

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing: 27 November 1997 (27.11.97)	
International application No.: PCT/EP97/02703	Applicant's or agent's file reference: WOB96 IDM APC
International filing date: 15 May 1997 (15.05.97)	Priority date: 21 May 1996 (21.05.96)
Applicant: CHOKRI, Mohamed et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International preliminary Examining Authority on:
08 November 1997 (08.11.97)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer: J. Zahra Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WOB96 IDMAPC	FOR FURTHER ACTION		See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)
International application No. PCT/EP97/02703	International filing date (day/month/year) 15/05/1997	Priority date (day/month/year) 21/05/1996	
International Patent Classification (IPC) or national classification and IPC C12N5/08			
Applicant I.D.M. IMMUNO-DESIGNED MOLECULES et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 6 sheets.

3. This report contains indications relating to the following items:

- | | | |
|------|-------------------------------------|---|
| I | <input checked="" type="checkbox"/> | Basis of the report |
| II | <input type="checkbox"/> | Priority |
| III | <input type="checkbox"/> | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| IV | <input type="checkbox"/> | Lack of unity of invention |
| V | <input checked="" type="checkbox"/> | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| VI | <input type="checkbox"/> | Certain documents cited |
| VII | <input type="checkbox"/> | Certain defects in the international application |
| VIII | <input checked="" type="checkbox"/> | Certain observations on the international application |

Date of submission of the demand 08/11/1997	Date of completion of this report 2 5. 08. 98
Name and mailing address of the IPEA/ <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465 </div> </div>	Authorized officer Bretherick, J Telephone No. (+49-89) 2399-8415



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP97/02703

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

Description, pages:

1-20 as originally filed

Claims, No.:

1-21 as received on 08/06/1998 with letter of 04/06/1998

Drawings, sheets:

1/1 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP97/02703

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims 1-13, 17-21
	No: Claims 14-16
Inventive step (IS)	Yes: Claims 1-13, 17- 21
	No: Claims 14-16
Industrial applicability (IA)	Yes: Claims 1-18, 21
	No: Claims 19, 20, opinion reserved

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP97/02703

1. The medium according to claim 14 is not distinguishable from that generally disclosed in for example, the example of WO94/26875 starting on page 11. This also applies to the kits or cell processors of claims 15 and 16. These claims are thus not novel under Art. 33(1)(2) PCT.
2. The method claims 6-10, although pertaining to MD-APCs according to any one of claims 1-5, do not include any technical features in the characterising portion of the claims **per se** to distinguish these from the techniques used in the above art example. It is important to note that the use of chemical ligands histidine and cimetidine or an H₂ receptor antagonist are only optional features in these claims. As a result these are not encompassed in the claimed scope **per se**.

Since the techniques categorised in the steps claimed might be used to arrive at both the prior art cell types and those of the current invention, two different products, the scope of protection covering the MD-APCs according to claim 11 which are obtainable (liable to be obtained) using [the steps of] methods 6-10, includes also the cell products of the disclosure of WO94/26875. Thus claim 11 is not clear under Art. 6 PCT. The same applies also to the subject-matter of 12, 13 and claims 17 and 18, which are products containing such cells, (cf. claims 16 and 17 of WO94/26875), as well as claims 19 and 20, (cf. claims 19 and 20 of WO94/26875).

3. The remaining claims appear to be novel and to involve an inventive step. It would appear that the cells express a number of characteristic cell markers at different ratios compared with those prepared according to the method of WO94/26875. The claims however, refer throughout to the term MD-APCs. This is not clear under Art. 6 PCT, since it is not recognised art terminology. The corresponding technical features should be introduced into the claims. Moreover, claim 21 refers to the term "chemical ligands of mononuclear cells". This is not a precise definition, resulting in a use claim with an unclear scope.

Finally, the expression of cell markers in terms of mean intensity is not clear under Art. 6 PCT, since it is not evident from the claims alone **precisely** which method has been used to determine the expression on the cell surface, nor what units should be applied.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP97/02703

4. An assessment of the medical treatment claims 19 and 20 is reserved under Art. 33(1)(4) PCT, since there are no clear, unified guidelines within the PCT for the assessment of industrial applicability of this type of subject-matter.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/08, A61K 35/14, C07K 16/46	A1	(11) International Publication Number: WO 97/44441 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/EP97/02703 (22) International Filing Date: 15 May 1997 (15.05.97) (30) Priority Data: 96401099.5 21 May 1996 (21.05.96) EP (34) Countries for which the regional or international application was filed: GB et al. (71) Applicant (for all designated States except US): I.D.M. IMMUNO-DESIGNED MOLECULES [FR/FR]; 172, rue de Charonne, F-75011 Paris (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): CHOKRI, Mohamed [MA/FR]; 9, rue de Bitche, F-67000 Strasbourg (FR). BARTHOLEYNS, Jacques [FR/FR]; 10, rue du Royaume, F-91440 Bures-sur-Yvette (FR). ROMET-LEMONNE, Jean-Loup [FR/FR]; 8, rue de Hesse, F-75003 Paris (FR). (74) Agent: GROSSET-FOURNIER, Chantal; Grosset-Fournier & Demachy S.A.R.L., 103, rue La Fayette, F-75481 Paris Cedex 10 (FR).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: NEW ANTIGEN PRESENTING CELLS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS CELLULAR VACCINES

(57) Abstract

The invention relates to monocytes derived antigen presenting cells (MD-APCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200; antigen CD80 and CD86 with a mean intensity of about 20 to about 200; antigen CD40 and mannose receptor with a mean intensity of 50 to 500; they are substantially devoid of the surface antigens CD1a and CD1c; they present a phagocytosis property; they have the property of stimulating the proliferation of allogenic lymphocytes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NEW ANTIGEN PRESENTING CELLS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS CELLULAR VACCINES.

The invention relates to new antigen presenting cells, a process for preparing the same and their use as cellular vaccines.

Macrophages are recognized since their description by Metchnikoff (Immunity in Infective Diseases, Cambridge Press, 1905) as cells which very effectively phagocytose (interiorise) and digest exogenous particles (antigens, cell debris, bacteria). They also secrete a variety of immunoeffector monokines. They have therefore a central role in initiating the non-specific and the specific immune responses. The recovery of large quantities of human macrophages differentiated in culture from blood monocytes has already been described (International application N° PCT/EP93/01232, refs. 1-6). These macrophages express typical antigens and functions and have been fully characterized (refs. 7-14).

Macrophages activated in the presence of IFN γ (Macrophage Activated Killers : MAK) elicited selective cytostasis and cytotoxicity for a large number of human tumors even at low effector/target ratio. In murine models, murine activated macrophages given locally in the tumor or its vicinity infiltrated the tumor mass, inhibited tumor growth and decreased metastatic development. Human macrophages also inhibited the growth of human tumors engrafted in nude or SCID mice ; this effect was achieved after local or systemic injection of a low number of macrophages (less than 1 million MAK) for mice with macroscopic tumors (ref. 15-20).

Patients with metastatic cancer were infused systemically or intraperitoneally with 10^8 to 4×10^9 autologous MAK. Tumoricidal monocytes (AKM) were also infused intraperitoneally in patients with colorectal carcinomas. The clinical tolerance of MAK was excellent with minor side effects such as low grade fever and chills and no autoimmune nor acute phase reactivity. No complete antitumoral response was reported ; improved prognosis and prolonged disease free intervals were described after intraperitoneal injection of AKM, while tumor necrosis, stabilisation, reduction of ascitic fluid and change in chemioresistance were seen after MAK therapy (refs. 21 - 26).

The recognized limitation of these macrophages is that they are not very potent in the priming of a specific immune response against a specific exogenous antigen or tumor by stimulation of MHC class I restricted cytotoxic

T lymphocytes (CD8 +). They are more efficient in presenting antigens in the context of MHC class II molecules to T helper lymphocytes (CD4 +).

However these macrophages have the potential to process and present soluble antigens by the exogenous pathway of phagocytes but high concentrations of proteins or antigens are required (refs. 38 - 42, 45 - 47, 50).

Cells expressing these functions of phagocytosis, digestion, processing, and presentation at a high level would be required for the development of cellular vaccines.

Dendritic cells are characterized by their morphology (dendrites) and a few membrane antigens, and are considered as professional antigen - presenting cells resident in tissues. They are the most potent cells for the stimulation of primary T - lymphocyte immune responses (refs. 43 - 44, 47 - 49, + Dendritic cells in fundamental and clinical immunology. 1995, Plenum Press N.Y., Banchemreau and Schmitt Editors).

Dendritic cell precursors arise from bone marrow and can be found in blood and lymph. Dendritic cells derived from these origins can be obtained by culture in the presence of GM - CSF + IL4 + TNF. They will then exhibit differences related to their maturation state and microenvironment.

The dendritic cells which can be derived from blood are most potent to induce allogenic mixed lymphocyte reactions and to stimulate naive T lymphocytes. However, these classical dendritic cells are technically relatively difficult to obtain and are poorly phagocytosing.

In contrast to macrophages, they do not express of CD14 and CD64 (high affinity F γ receptor).

To circumvent the problem of poor phagocytoses and processing of particular antigens by dendritic cells, these cells have been pulsed with small peptides fixed on MHC-I molecules to induce primary immune reaction and vaccination against new antigenic peptides (ref. 51).

Obtaining dendritic cells by *in vitro* differentiation requires the presence of GM-CSF and of a second cytokine that can be IL 4 (ref. 44) or IL 13 (ref. 49), plus TNF.

One of the aims of the invention is to provide cells with high phagocytosis, and efficient antigen presentation.

Another aim of the invention is to provide very potent antigen presenting cells derived from human blood monocytes.

Another aim of the invention is to provide cells presenting membrane receptors, allowing targeting and increased antigen presentation with the use of bispecific antibodies (refs. 27 - 31, 37).

Another aim of the invention is to provide cells which can be transfected with cDNA to be used in gene therapy (ref. 32 - 36).

Another aim of the invention is to provide a method allowing the recovery from human blood of cells of the macrophage lineage with high phagocytosis, digestive activity, processing MHC class I and class II antigen presentation (ref. 46, 50, 52).

Another aim of the invention is to provide a reproducible method allowing to obtain the above defined cells, said process not requiring combination of exogenous cytokines, defined media and recipients constituting a cell processor.

Another aim of the invention is to provide cellular vaccines demonstrating the high phagocytosis, processing, MHC-II peptide presentation of the macrophages and also the potent MHC-I T lymphocyte stimulation with high level of accessory molecules for presentation of the dendritic cells.

The invention relates to macrophages which have the following properties :

- they present on their surface :

* antigen CD14 with a mean intensity of about 20 to about 200,

* antigen CD64 with a mean intensity of about 20 to about 200,

- they are substantially devoid of the surface antigens CD1a and CD1c,

the presence and mean intensities respectively of CD14, CD64 and the absence of CD1a and CD1c being for instance determined by immunofluorescence staining and flow cytometry analysis,

- they present a phagocytosis property such as determined by the following test: said phagocytosis capacity being evaluated by an uptake of formalin fixed yeast, for example by culturing macrophages for 2 hours, adding yeast in 1/10 macrophage/yeast ratio and incubating at 37°C, 5% CO₂ atmosphere for 2-3 hours fixing by the May-Grünwald-Giemsa (MGG) staining, and the percentage of phagocytic macrophages being quantified for instance by microscopic analysis,

- they have the property of stimulating the proliferation of allogenic lymphocytes such as determined by the following test :

allogenic primary mixed lymphocytes reaction (MLR) was carried out in 96-well microtiter plates by adding increasing numbers (2×10^3 to 2×10^5) in 100 μ l medium/well of macrophages to 2×10^5 in 100 μ l medium/well of allogenic T cells purified from buffy coats and after 5 days incubation at 37°C, cell proliferation was assessed by a colorimetric method, such as the hydrolysis of tetrazolium salt WST-1 (Boehringer Mannheim, Germany), (slightly red) to Formozan (dark red).

More generally, the invention relates to monocytes derived antigen presenting cells (MD-APCs), particularly macrophages which have the following properties :

- they present on their surface :

5 * antigens CD14 and CD64 with a mean intensity of about 5 to about 200,
 * antigen CD80 and CD86 with a mean intensity of about 20 to about 200,

 * antigen CD40 and mannose receptor with a mean intensity of 50 to 500,

- they are substantially devoid of the surface antigens CD1a and CD1c,

10 the presence and mean intensities respectively of CD14, CD64, CD80 and CD86, and the absence of CD1a and CD1c being for instance determined by immunofluorescence staining and flow cytometry analysis,

- they present a phagocytosis property such as determined by the following test: said phagocytosis capacity being evaluated by an uptake of formalin fixed yeast,
15 for example by culturing MD-APCs for 2 hours, adding yeast in 1/10 MD-APCs/yeast ratio and incubating at 37°C, 5% CO₂ atmosphere for 2-3 hours fixing by the May-Grünwald-Giemsa (MGG) staining, and the percentage of phagocytic MD-APCs being quantified for instance by microscopic analysis,

20 - they have the property of stimulating the proliferation of allogenic lymphocytes such as determined by the following test :

allogenic primary mixed lymphocytes reaction (MLR) was carried out in 96-well microtiter plates by adding increasing numbers (2×10^3 to 2×10^5) in 100 μ l medium/well of MD-APCs to 2×10^5 in 100 μ l medium/well of allogenic
25 T cells purified from buffy coats and after 5 days incubation at 37°C, cell proliferation was assessed by measurement of Brdu incorporation during DNA synthesis by ELISA method (Boehringer Mannheim, Germany).

In the context of the present invention, the expression "macrophages" designates not only macrophages but antigen presenting cells which derive from monocytes and which will be hereafter designated by MD-APC.
30

The expression "substantially devoid of surface antigens CD1a and CD1c" means either that there is no such surface antigens or that there is only a dim intensity for these surface antigens, with said dim intensity corresponding to about 10 times less than the intensity obtained in the presence of such surface
35 antigens, as determined in immunofluorescence analysis, or with said intensity being lower than 20.

In the following of the text, it will be often referred to "the absence of surface antigen CD1a and CD1c", which is to be understood as "substantially devoid of such antigens" as explained above (intensity lower than 20).

The invention also relates to MD-APCs which present, on their surface, antigen MHC-II with a mean intensity of about 100 to about 600, such as determined by immunofluorescence staining and flow cytometry analysis.

The invention also relates to macrophages which are substantially devoid of surface antigen CD83, such as determined by immunofluorescence staining and flow cytometry analysis.

The expression "substantially devoid of surface antigen CD83" corresponds to an intensity lower than 20.

The MD-APCs of the invention present adherent properties such as determined by the following test :

the MD-APCs are cultured for 2 h in culture medium (I.M.D.M. or R.P.M.I.) on plastic flasks and the percentage (%) of adherent cells is quantified for instance by microscopic analysis.

The culture media I.M.D.M. and R.P.M.I. are commercially available.

The invention relates to a MD-APCs culture wherein :

- about 10% to about 50% of the MD-APCs present antigen CD14 on their surface,
- about 10% to about 50% of the MD-APCs present antigen CD64 on their surface,
- about 80% to about 100% of the MD-APCs present antigen MHC-II on their surface,
- about 70% to about 100% of the MD-APCs present adherent properties,
- about 30% to about 100% of the MD-APCs present antigens CD80 and CD86 on their surface,
- about 30% to about 100% of the MD-APCs present high phagocytosis property,

each macrophage having the above-mentioned properties being such that said properties are expressed according to the intensities as specified above.

The invention also relates to a process for preparing a composition of macrophages which comprises the culture of mononuclear cells in a culture medium containing histamine or histamine agonist (H_1 in action) and a H_2 antagonist, in combination or not with "additional" GM-CSF.

The invention also relates to a process for preparing a composition of MD-APCs which comprises the culture of mononuclear cells in a culture medium containing a chemical ligand having receptors on the membrane of

mononuclear cells; for example histamine or histamine agonist (H_1 in action) and a H_2 antagonist, in combination or not with "additional" GM-CSF.

An example of histamine agonist is 2 methyl-histamine.

5 The expression "additional" corresponds to the fact that there is no GM-CSF added to the culture in standard condition, but this does not exclude the fact that exogenous GM-CSF could be added in the culture to increase yield and functions of MD-APCs obtained.

As example of H_2 antagonist, one may cite cimetidine but also tiotidine, burimamide, metiamide, ranitidine.

10 As example of other chemical ligands interacting with mononuclear cells and allowing differentiation into MD-APCs, one may cite detoxified LPS such as lipid A, C3 and other ligands of complement receptors, taxols, oxydoreductors such as flavenoids or polyphenols, ligands to CD40, to the TNF receptors or to vitamin D3 receptors.

15 The invention also relates to a process wherein the culture medium contains chemical ligands, such as histamine and cimetidine or a H_2 antagonist without "additional" GM-CSF, histamine being present at a concentration of about 10^{-2} M to about 10^{-6} M, preferably of about 10^{-4} M, and cimetidine or the H_2 antagonist being present at a concentration of about 10^{-4} M to about
20 10^{-9} M, preferably of about 10^{-6} M.

When the concentration of histamine or cimetidine or other chemical ligands for membrane receptors is lower than the lower value of the given range, there is substantially no effect, i.e. less than 10% difference with cells cultured in the absence of histamine and cimetidine.

25 When the concentration of histamine or cimetidine is higher than the higher value of the given range, the culture medium becomes toxic.

When no additional GM-CSF is incorporated into the culture medium, GM-CSF secreted *in situ* by the MD-APCs can be present at a concentration of about 5 to about 500 U/ml.

30 The invention also relates to a process wherein the culture medium contains a chemical ligand, for example histamine and cimetidine or a H_2 antagonist, in combination with "additional" GM-CSF, histamine being present at a concentration of about 10^{-2} M to about 10^{-6} M, preferably of about 10^{-4} M, cimetidine or the H_2 antagonist being present at a concentration of
35 about 10^{-4} M to about 10^{-9} M, preferably of about 10^{-6} M, and additional GM-CSF being present at a concentration of about 50 U/ml to about 1000 U/ml, preferably of about 500 U/ml.

When additional GM-CSF is incorporated into the culture, then the total concentration of GM-CSF is from about 50 U/ml to about 2000 U/ml, and preferably from about 50 U/ml to about 500 U/ml.

According to a particular embodiment of the invention, the culture medium does not comprise the following elements : exogenous cytokines such as IL4, IL10, TNF.

The invention also relates to a process comprising :

- isolation of leukocytes, from healthy donors or from patients, from peripheral blood by apheresis and removal of platelets and anticoagulant from the apheresis product,
- isolation of mononuclear cells (monocytes + lymphocytes) from red cells and granulocytes in order to have less than 10% granulocytes and less than 5% red cells,
- culture of the mononuclear cells obtained at the previous stage by placing them in an appropriate culture medium containing a chemical ligand of mononuclear cells, such as histamine or an agonist of histamine, an H₂ antagonist, such as cimetidine, in combination or not with GM-CSF, for a time sufficient to obtain differentiated MD-APCs, preferably for about 5 to 15 days, and possibly separating the MD-APCs from the lymphocytes, and recovering the MD-APCs or the MD-APCs and lymphocytes.

The invention also relates to a process wherein the culture medium of MD-APCs is added

- with crude antigens, for instance autologous tumor membrane, killed tumoral cells, bacterial capsides, viral homogenates cleared from nucleic acids,
- specific peptides against which an immune response is desired,
- cDNA or genetic material linked to vectors (for example gluconated polylysine) to allow transfection of the macrophage with material coding for the relevant peptide or protein to be presented on the MD-APCs membrane and against which an immune response is desired,
- or bispecific antibodies targeting on the one side, a surface antigen or a surface receptor of the MD-APCs and, on the other side, a relevant antigen against which an immune response is desired.

The invention also relates to MD-APCs liable to be obtained according to the process of the invention described hereabove.

The invention also relates to pharmaceutical compositions containing as active substance, MD-APCs according to the invention.

The invention also relates to cellular vaccine compositions containing as active substance, MD-APCs according to the invention.

The invention also relates to the medium containing elements necessary for the growth and differentiation of monocytes into MD-APCs according to the invention, and in addition containing chemical ligands of mononuclear cells, such as histamine, cimetidine in combination or not with GM-CSF.

5 As example of other chemical ligands interacting with mononuclear cells and allowing differentiation into MD-APCs, one may cite detoxified LPS such as lipid A, C3 and other ligands of complement receptors, taxols, oxydoreductors such as flavenoids or polyphenols, ligands to CD40, to the TNF receptors or to vitamin D3 receptors.

10 The invention also relates to a cell processor or a kit containing :
- means for the recovery of lymphocytes and monocytes free of contaminants,
- appropriate buffer and wash solutions and possibly appropriate means for the conservation of macrophages,
- means for preparing a culture for the monocytes and possibly the lymphocytes
15 and containing chemical ligands of mononuclear cells, for example histamine, cimetidine or a H₂ antagonist in combination or not with GM-CSF,
- possibly means for transfection of cultured cells and means for targeting antigens to MD-APCs.

20 Regarding the conservation of MD-APCs, it can include freezing means for example in 10% glycerol or D.M.S.O. (dimethyl sulfoxide) in the presence of autologous or AB⁺ serum.

The invention also relates to a cell processor or a kit as described above which contains :

25 - means for recovering and centrifuging blood to obtain a leukocyte concentrate,
- means for separating lymphocytes and monocytes from the other white cells and for eliminating the contaminating red cells,
- culture medium for MD-APCs and possibly lymphocytes with complements and particularly chemical ligands of mononuclear cells, such as histamine and cimetidine or a H₂ antagonist, in combination or not with GM-CSF,
30 - appropriate means for the conservation of macrophages,
- appropriate buffer and wash solution.

The invention also relates to products containing MD-APCs according to the invention, and lymphocytes, as a combined preparation for simultaneous, separate or sequential use in cell therapy.

35 The invention also relates to products as described hereabove which contain the MD-APCs and the lymphocytes in a ratio of at least 20% to 50% of MD-APCs expressed in cell number.

The invention also relates to bispecific antibodies liable to recognize an antigen of a MD-APCs of the invention and an antigen of a tumoral cell or of a pathogen which is to be targetted to said MD-APCs.

The invention also relates to a method for the clinical treatment, comprising the administration of an appropriate amount of MD-APCs according to the invention, and preferably in an amount of about 10^8 to about 5×10^9 MD-APCs.

The invention also relates to a method for the treatment of any disorder, comprising the administration of lymphocytes from the culture in an amount of about 4×10^9 to about 10×10^9 lymphocytes.

The invention also relates to the use of a chemical ligands of mononuclear cells, such as an agonist of histamine receptor, in particular histamine, and a H_2 antagonist, in particular cimetidine, in combination or not with GM-CSF, for the preparation of MD-APCs having the following properties :

- they present on their surface :

* antigens CD14 and CD64 with a mean intensity of about 5 to about 200,

* antigen CD80 and CD86 with a mean intensity of about 20 to about 200,

* antigen CD40 and mannose receptor with a mean intensity of 50 to 500,

- they are substantially devoid of the surface antigens CD1a and CD1c, the presence and mean intensities respectively of CD14, CD64, CD80, CD86 and the absence of CD1a and CD1c being for instance determined by immunofluorescence staining and flow cytometry analysis,

- they present high phagocytosis property such as determined by the following test:

said phagocytosis capacity being evaluated by an uptake of formalin fixed yeast, for example by culturing MD-APCs for 2 hours to select adherent cells, adding yeast in 1/10 macrophages to yeast ratio and incubating at 37°C , 5% CO_2 atmosphere for 2-3 hours fixing by the May-Grünwald-Giemsa (MGG) staining, and the percentage of phagocytic MD-APCs being quantified for instance by microscopic analysis,

- they have the property of stimulating the proliferation of allogenic lymphocytes such as determined by the following test :

allogenic primary mixed lymphocytes reaction (MLR) was carried out in 96-well microtiter plates by adding different numbers 2×10^3 to 2×10^5 in $100 \mu\text{l}$ medium/well of MD-APCs to 2×10^5 in $100 \mu\text{l}$ medium/well of allogenic T cells purified from buffy coats and after 5 days incubation at 37°C , cell proliferation

was assessed by a colorimetric method, such as the cleavage of tetrazolium salt WST-1 (slightly red) to Formozan (dark red).

The monocytes derived antigens presenting cells of the invention and the MD-APCs can be obtained as follows :

5 a) Isolation of leukocytes from blood by apheresis and elimination of platelets, by centrifugation. If cells collected have < 10% granulocytes and haematocrit < 5%, they can be seeded as such in culture. Otherwise mononuclear cells have to be prepared first by centrifugation on Ficoll Paque of density 1,077.

10 b) Mononuclear cells are then cultured for 5 to 15 days in hydrophobic bags ethylene vinyl acetate (E.V.A., Stedim) or polypropylene (Life Cell, Baxter), at 37°C, 5% CO₂. Cells are seeded at 5.10⁶/ml in I.M.D.M. (as previous) or equivalent medium supplemented with indomethacin (5x10⁻⁶M) mercaptoethanol (3x10⁻⁵M), non essential amino-acids (1%, Gibco) and 2 to 15 5% of reconstituted autologous *or* AB⁺ serum,

. with GM-CSF, 500 U/ml chemical ligands interacting with mononuclear cells and allowing differentiation into MD-APCs, such as detoxified LPS such as lipid A, C3 and other ligands of complement receptors, taxols, oxydoreductors such as flavenoids or polyphenols, ligands to CD40, to the 20 TNF receptors or to vitamin D3 receptors ; as example of ligands, histamine (10⁻⁴ M), cimetidine (10⁻⁶ M) or another H₂ antagonist of histamine, or with histamine, cimetidine in the absence of any exogenous cytokines. Endogenous cytokines are released by mononuclear cells stimulated by ligands.

. and exogenous antigens, peptides or transfectants (cDNA + vector) 25 coding for the relevant antigen.

c) After culture, the specific monocyte derived antigen presenting cells (MD-APCs) are centrifuged, washed and resuspended for injection in the patient, to induce humoral and cellular immune response against the antigen.

The specificity of the cellular vaccine is achieved during the *in vitro* 30 culture according to one of the following items.

a) culture of MD-APCs as explained above in b), in the presence of crude antigens, for example autologous tumor membrane, bacterial capsides, viral homogenates cleared from nucleic acids ;

b) culture of MD-APCs as explained above in b), in the presence of 35 specific peptides against which immune response would be beneficial,

c) or culture of MD-APCs as explained above in b), in the presence of cDNA or genetic material linked to vectors (for example gluconated

polyphsine) to allow transfection of MD-APCs with material coding for the relevant peptide or protein to be presented on the membrane.

In order to obtain specific cellular vaccine, it is also possible at the end of the differentiation stage of the macrophage culture to add bispecific antibodies targeting a membrane antigen, or a surface receptor of MD-APCs on one side and the relevant antigen on the other side.

According to a preferred embodiment, the process of the invention comprises the following steps:

- isolation of leukocytes from blood of healthy subjects or patients by apheresis, to obtain the apheresis products (i.e. concentrated leukocytes),

- platelet elimination, for instance by centrifugation of the apheresis products, to obtain a leukocyte enriched product,

- separation, in the leukocyte enriched products, of the mononuclear cells on one hand, and of the contaminating red blood cells and granulocytes on the other hand,

- culture of the mononuclear cells (monocytes + lymphocytes) in a medium containing chemical ligands of mononuclear cells, such as histamine and cimetidine and GM-CSF for about 5 to 15 days, to obtain differentiated monocyte derived antigen presenting cells (MD-APCs).

The lymphocytes can be separated from the monocytes before the culture step.

The lymphocytes can be separated from the MD-APCs after the culture.

In the process of the invention, chemical ligands for mononuclear cells, such as histamine are used at a concentration of 10^{-2} M to about 10^{-6} M, preferably of about 10^{-4} M.

In the process of the invention, GM-CSF is used at a concentration of about 50 to about 1000 U/ml, particularly of about 100 to about 500 U/ml.

In the process of the invention, the culture medium is RPMI, IMDM, MEM, or DMEM selected for very low endotoxin content.

These media are commercially available.

Advantageously, the culture medium contains indomethacin (or another cyclo-oxygenase inhibitor) or/and cimetidine (an histamine H₂ antagonist) and/or at other chemical ligands of mononuclear cells.

An advantageous process for preparing the MD-APCs of the invention is the following:

Apheresis

Leukocytes from healthy subjects or from patients are isolated from peripheral blood by apheresis using the Cobe Spectra continuous-flow blood cell

separators keeping granulocytes contamination very low (< 10% and less than 5% red cells). The apheresis product is centrifuged for 10 min at 280 g in order to reduce platelet contamination. The platelet-enriched plasma is removed and leukocyte pellet resuspended in a phosphate buffer solution (PBS) containing
5 0.1% glucose, 0.17% PO_3HNa_2 , $2\text{H}_2\text{O}$, 0.27% $\text{PO}_3\text{H}_2\text{Na}$, 0.14% NH_4Cl , 0.78% NaCl (solution TS745 laboratoire Bruneau, France).

The enriched leukocyte pellet is obtained with an average of 7 to 1.5×10^{10} leukocytes (50% of mononuclear cells).

Isolation of mononuclear cells

10 If the collected leukocytes have more than 10% granulocytes contamination and/or 5% hematocrite, human mononuclear cells are separated from red blood cells and from contaminating granulocytes, by 15 min centrifugation at 1000 g on a COBE 2991 or Stericell cell processor using Ficoll Paque of density 1.077 (Pharmacia). After 3 washings in phosphate buffered
15 saline solution without calcium and magnesium, the monocytes are obtained with about 20% to 50% purity as shown by channelyser analysis (Coulter Margency-France).

Culture

20 Differentiated human MD-APC are obtained by 5-15 days in culture of mononuclear cells in hydrophobic bags in E.V.A. (Ethylene Vinyl Acetate, STEDIM, Aubagne) or polypropylene (life cell-Baxter) at 37°C and 5% CO_2 , 95% humidified atmosphere. Total mononuclear cells are seeded at 5×10^6 cells/ml in Iscove modified medium (I.M.D.M., Gibco) or equivalent medium supplemented by penicillin (100 UI/ml), streptomycine (100 $\mu\text{g}/\text{ml}$),
25 L-glutamine (2 mM, Gibco), pyruvic acid (2 mM, Gibco), Indomethacin (5×10^{-6} M, Sigma), cimetidine (10^{-8} to 10^{-4} M), histamine (10^{-6} to 10^{-2} M or other chemical ligands), mercaptoethanol (3×10^{-5} M, Gibco) non-essential amino-acids (1%, Gibco) and 2-5% of autologous or AB serum. The addition of GM-CSF (500 U/ml, SANDOZ) was done in comparative experiment.

30 According to a preferred embodiment, the process of the invention is such that killed tumoral cells are added into the culture medium simultaneously with monocytes, both cells coming preferably from the same patient, preferably at the ratio of about 1 million of killed tumoral cells/ml, with said killed tumoral cells being processed at the same time as macrophages.

35 The killed tumoral cells can then be processed simultaneously with the leukocytes, in an amount of about $1 \times 10^6/\text{ml}$.

This process allows to obtain MD-APCs and lymphocytes specific for the tumor, inducing very efficiently *in vivo* an immune response to these specific tumor cells.

5 The invention also relates to MD-APCs liable to be obtained according to the above-defined process.

The invention also relates to pharmaceutical compositions containing, as active substance, MD-APCs as defined above.

10 The invention also relates to a medium containing elements necessary for the growth and differentiation of monocytes into MD-APCs of the invention, and in addition chemical ligands for mononuclear cells, for example histamine and GM-CSF.

The monocyte derived antigens presenting cells of the invention can be part of a cell processor or a kit containing:

15 - means for the recovery of lymphocytes and monocytes free of contaminants;

- appropriate buffer and wash solutions, and possibly appropriate means for the conservation of MD-APCs ;

20 - means for preparing a culture medium for the monocytes and possibly the lymphocytes and containing chemical ligands for mononuclear cells, for example histamine and/or GM-CSF.

According to an advantageous embodiment of the invention, the cell processor or kit contains :

- means for recovering and centrifuging blood to obtain a leukocyte concentrate;

25 - means for separating lymphocytes and monocytes from the other white cells and for eliminating the contaminating red cells;

- culture medium for MD-APCs and possibly lymphocytes with complements and particularly and/or GM-CSF and possibly indomethacin and/or cimetidine ;

30 - appropriate means for the conservation of the MD-APCs ;

- appropriate buffer and wash solutions ;

The invention also relates to products containing MD-APCs according to the invention, and lymphocytes, as a combined preparation for simultaneous, separate or sequential use in adoptive immunotherapy.

35 According to an advantageous embodiment, the products of the invention as defined above are characterised in that they contain the MD-APCs and the lymphocytes in a ratio of at least 20% to 50% of MD-APCs expressed in cell number.

In this embodiment, the MD-APCs and the lymphocytes are both injected to a patient.

The invention also relates to bispecific antibodies liable to recognize an antigen of a MD-APC of the invention, for example FC γ RI (CD 64) and an antigen of a relevant antigen.

The bispecific antibodies can be prepared as described in Chokri et al. Res. Immunol. 143 (1992).

The bispecific antibodies can be injected at the same time as the MD-APCs of the invention, or can be pre-incubated with MD-APCs before injection.

The invention also relates to a method for the treatment of cancer and pathogens comprising the administration of an appropriate amount of MD-APCs according to the invention, and preferably in an amount of about 1×10^8 to about 5×10^9 MD-APCs.

Description of the Figure :

Figure 1a represents the allogenic T cell proliferation induced by MD-APCs of the invention recovered in the presence of histamine (10^{-4} M) and cimetidine (10^{-6} M) as adjuvant, with or without GM-CSF (500 U/ml) comparing to standard macrophages produced only in the presence of the GM-CSF (500 U/ml).

Figure 1b represents the stimulation by MD-APCs recovered in the presence of GM-CSF or GM-CSF + IL-13.

In Figure 1a, the optical density (450-690 nm) has been plotted against the ratio between the MD-APCs of the invention and the responder lymphocyte cells.

The clear dotted bars correspond to the presence of GM-CSF at 500 U/ml; the lighter grey bars correspond to the presence of histamine (10^{-4} M) and cimetidine (10^{-6} M).

The darker grey bars correspond to the presence of GM-CSF (500 U/ml), in combination with histamine (10^{-4} M) and cimetidine (10^{-6} M).

The results show that the capacity of the MD-APCs to stimulate the proliferation of allogenic lymphocytes is strongly increased. The stimulation of allogenic proliferation of lymphocytes by MD-APCs is very potent (at least 200% increase with respect to standard macrophages). The combination of histamine/cimetidine effect or IL-13 effect with GM-CSF can potentiate this activity (maximum of 300% increase with respect to the induction by macrophages).

In Figure 1b, the optical density (450-690 nm) has been plotted against the ratio between the MD-APCs of the invention and the responder lymphocyte cells. The curve with dark circles corresponds to the presence of GM-CSF/IL-13 and the curve with open circles correspond to the presence of GM-CSF.

EXAMPLE : Preparation of MD-APCs according to the invention :

1- Apheresis:

Leukocytes from healthy donors or from patients are isolated from peripheral blood by apheresis using COBE spectra blood cell separator keeping granulocytes contamination the lowest possible. The apheresis product is diluted in a phosphate buffered solution (PBS) (final volume = 450 ml). The apheresis product is centrifuged for 10 min at 280 g to remove platelets and anticoagulant.

2- Isolation of mononuclear cells:

If the collected cells have > 10% granulocytes contamination and/or > 5% haematocrit, they should be centrifuged over Ficoll (density = 1.077) to remove red cells and granulocytes.

3- Culture

The monocyte derived antigen presenting cells (MD-APCs) are obtained after 5 to 15 days in culture of mononuclear cells in hydrophobic bags in EVA (Ethylene Vinyl Acetate /STEDIM) or equivalent bags (Teflon) at 37°C and 5% CO₂ in humidified atmosphere. The mononuclear cells are seeded at 5x10⁶ cells/ml in Iscove modified medium (I.M.D.M. - Gibco) or equivalent supplemented by (see PCT/EP93 page 7) the addition of ligands for mononuclear cells, such as histamine (10⁻⁴ M) or analogues and cimetidine (10⁻⁶ M) or similar H₂ antagonist, in the presence or not of GM-CSF (500 U/ml).

As example of other chemical ligands interacting with mononuclear cells and allowing differentiation into MD-APCs, one may cite detoxified LPS such as lipid A, C3 and other ligands of complement receptors, taxols, oxydoreductors such as flavenoids or polyphenols, ligands to CD40, to the TNF receptors or to vitamin D3 receptors.

4- Characterization and functionality

a- Flow cytometry

After the maturation of MD-APCs, the phenotype analysis of the obtained cells was performed by flow cytometry using murine FITC or P.E labelled monoclonal antibodies directed against membrane proteins.

b- Mixed lymphocytes reactions (MLR)

To evaluate the induction of T cell response to MD-APCs, allogenic primary MLR was carried out in 96-Well microtiter plates by adding different numbers of MD-APCs to 2×10^5 allogenic T cells purified from buffy coats. After 5 days at 37°C , cell proliferation was assessed by a colorimetric methods such as WST-1.

c- Phagocytosis

The phagocytic capacity of the different cells obtained was evaluated by uptake of formalin fixed yeast. Briefly the cells were cultured for 2 hours to select adherent cells. The yeast was added at 1/10 macrophage/yeast ratio and incubated in 37°C , 5% CO_2 atmosphere for 2-3 h and then fixed by the May-Grünwald-Giemsa (MGG) staining. The percentage of phagocytic cells was quantified by microscopic analysis.

The results are gathered in table 1, table 2 and table 3.

Table 1
Yield (% of cells) differentiated in culture

Time of culture	(a) Hist/Cim	(b) Hist.Cim/GM
Day 4	71%	78%
Day 7	49%	48%
Day 11	19%	31%

Table 1 shows that there is a recovery of a large quantity of MD-APCs after 5 to 11 days of culture of mononuclear cells in hydrophobic bags, in the presence of histamine (10^{-4} M) and cimetidine (10^{-6} M) (a) and additional GM-CSF (500 U/ml) (b) as adjuvant. In comparison with production of mature macrophages in standard conditions, the recovery of MD-APC cells is in the same order.

Table 2
Phenotype of MD-APCs
produced under various conditions after 6 days of culture

Surface Ag	(a)		(b)	
	Hist/Cim		Hist.Cim/GM-CSF	
	%	MIF	%	MIF
CD1a	N		N	
CD1c	N		N	
CD83	N		N	
CD14	95	114	95	92
CD 54	96	40	96	40
CD 58	97	41	97	31
CD 64	43	35	91	46
HLA-DR	92	350	96	400

MIF = Mean Intensity Fluorescence.

% = percentage of positive cells.

N = Negative or weak signal.

This table corresponds to the immunofluorescence profile analysis by flow cytometry of MD-APCs generated in culture (6 days) under different conditions. The cells obtained under histamine (10^{-4} M) and cimetidine (10^{-6} M) conditions (a) are positive for macrophage markers (CD14, CD64 and HLA-DR). The combination with GM-CSF (b) does not change the phenotypic profile of the MD-APCs. They also clearly express CD54 and CD58. The CD80 (B7.1) and CD86 (B7.2) are also expressed on their membrane but in lower level. In contrast, CD1a, CD1c and CD83 which are positive markers of dendritic cells, are weakly expressed by the MD-APCs.

From these data, it can be confirmed that the antigen presenting cells generated in the culture system of the invention are different from dendritic cells.

Table 3

% of phagocytic cells after 3 h contact with fixed yeast

Number of intracellular Yeast	(a) Hist/cim	(b) Hist.Cim/GM-CSF
0	42 %	20 %
1-5	43.6 %	43 %
6-10	11 %	27.5 %
> 10	3.4 %	9.5 %

The MD-APCs are tested for the phagocytic activity using formalin fixed yeast. After 3 h incubation and MGG (May Grünwald Giemsa) staining, the intracellular particles are quantified by microscopic analysis. The MD-APCs generated in the presence of histamine/cimetidine (a) present an important capacity of phagocytosis (60%) and this capacity is increased in the presence of GM-CSF in the culture (80%) (b).

From the above-mentioned results, it is shown that human mononuclear cells cultured in the presence of histamine and cimetidine, in combination or not with GM-CSF mainly for one week, differentiate into mature antigen presenting cells. During the culture, these cells acquire a high level of accessory functions like.

The results of the invention indicate that the MD-APCs obtained in the culture system of the invention are different from the dendritic cells (DC), since DC have been described as FC (CD64) receptor negative, poorly adherent and non-phagocytic cells, possessing only a small number of lysosomes.

In contrast the MD-APCs of the invention :

- (a) show a high adherence capacity,
- (b) show an important phagocytic and processing activity,
- (c) express high level HLA-DR membrane antigens and a low level of CD1a and CD1c, which is strongly expressed by dendritic cells,

(d) are also positive for CD54, CD58, CD80 and CD86 membrane antigens,

(e) stimulate T-cell proliferation in allogenic MLR reaction, and this is in a far better way than macrophages obtained according to techniques of the prior art.

Table 4 hereafter gathers the comparative characterization of MD-APC of the invention on the one hand, and of dendritic cells on the other hand.

Table 4
Comparative characterization of Antigen Presenting Cells:

	Dendritic Cells		MD-APC	
			% cells	Intensity
Phenotype				
CD1a	+	-	0	
CD1c	+	-	0	
CD 83	+	-	0	
CD14	+/-	+	10 to 100	5 to 200
CD64	-	+	10 to 100	5 to 200
CMH-II	+++	+++	80 to 100	100 to 400
Functions:				
Adherence	-	++	70 to 90 %	
Phagocytosis	-	++	30 to 80 %	
Stimulation of MLR	+++	++		

Table 5

It gathers a complete phenotypic characterization of MD-APCs recovered after 6 days of culture according to the invention (analysis by flow cytometry).

Phenotype	% Cells	Mean fluo intensity
CD45	97,6	172
CD14	6,8	
CD3	13	
CD19	15	
CD56	3,8	
CD4-PE	95	
CD25	1,7	
CD45RO	99	
CD16	1,8	31
CD32	63	163
CD64	4	12
CD1a	31	216
CD1c	58	505
CD83	9	18
HLA-DR	99	266
HLA-I	99,6	582
CD40	98	991
CD80	78	64
CD86	99	744
IgG1-FITC	6,7	11
IgG1-PE	20	(16)55
IgG1-Cy5	19	(29)50
IgG2a-FITC	5,3	19
IgG1 i	1,6	75
IgG2a i	3,8	21
IgG2b i	3,2	15

CLAIMS

1. MD-APCs which have the following properties :

- they present on their surface :

* antigen CD14 and CD64 with a mean intensity of about 5 to about 200,

* antigen CD80 and CD86 with a mean intensity of about 20 to about 200,

* antigen CD40 and mannose receptor with a mean intensity of 50 to 500,

- they are substantially devoid of the surface antigens CD1a and CD1c,

the presence and mean intensities respectively of CD14, CD64, CD80, CD86 being for instance determined by immunofluorescence staining and flow cytometry analysis,

- they present a phagocytosis property such as determined by the following test: said phagocytosis capacity being evaluated by an uptake of formalin fixed yeast, for example by culturing macrophages for 2 hours, adding yeast in 1/10 macrophages/yeast ratio and incubating at 37°C, 5% CO₂ atmosphere for 2-3 hours fixing by the May-Grünwald-Giemsa (MGG) staining, and the percentage of phagocytic MD-APCs being quantified for instance by microscopic analysis,

- they have the property of stimulating the proliferation of allogenic lymphocytes such as determined by the following test :

allogenic primary mixed lymphocytes reaction (MLR) was carried out in 96-well microtiter plates by adding different numbers (2×10^3 to 2×10^5 in 100 μ l medium/well) of MD-APCs to 2×10^5 in 100 μ l medium/well of allogenic T cells purified from buffy coats and after 5 days incubation at 37°C, cell proliferation was assessed by a colorimetric method, such as the hydrolysis of tetrazolium salt WST-1 (Boehringer Mannheim, Germany), (slightly red) to Formozan (dark red).

2. MD-APCs according to claim 1, which present, on their surface, antigen MHC-II with a mean intensity of about 100 to about 400, such as determined by immunofluorescence staining and flow cytometry analysis.

3. MD-APCs according to any one of claims 1 or 2, which are substantially devoid of surface antigen CD83, such as determined by immunofluorescence staining and flow cytometry analysis.

4. MD-APCs according to any one of claims 1 to 3, which present adherent properties such as determined by the following test :
the macrophages are cultured for 2 h in culture medium (I.M.D.M. or R.P.M.I.) on plastic flasks and the percentage (%) of adherent cells is quantified for instance by microscopic analysis.

5. MD-APCs culture wherein :

- about 10% to about 50% of the MD-APCs present antigen CD14 on their surface,
 - about 10% to about 50% of the MD-APCs present antigen CD64 on their surface,
 - about 30% to about 100% of the MD-APCs present antigens CD80 and CD86 on their surface,
 - about 80% to about 100% of the MD-APCs present antigen MHC-II on their surface,
 - about 70% to about 100% of the MD-APCs present adherent properties,
 - about 30% to about 100% of the MD-APCs present a phagocytosis property,
- each MD-APCs having the above-mentioned properties being such that said properties are expressed according to the intensities as specified in any one of claims 1 to 4.

6. Process for preparing a composition comprising MD-APCs according to any one of claims 1 to 5, comprising the culture of mononuclear cells in a culture medium containing chemical ligands of mononuclear cells, such as histamine or histamine agonist and a H_2 antagonist, in combination or not with "additional" GM-CSF, or other chemical ligands interacting with mononuclear cells and allowing differentiation into MD-APCs, such as detoxified LPS such as lipid A, C3 and other ligands of complement receptors, taxols, oxydoreductors such as flavenoids or polyphenols, ligands to CD40, to the TNF receptors or to vitamin D3 receptors.

7. Process according to claim 6, wherein the culture medium contains chemical ligands of mononuclear cells, for example histamine and cimetidine or a H_2 antagonist without "additional" GM-CSF, histamine being present at a concentration of about 10^{-2} M to about 10^{-6} M, preferably of about 10^{-4} M, and cimetidine or the H_2 antagonist being present at a concentration of about 10^{-4} M to about 10^{-9} M, preferably of about 10^{-6} M.

8. Process according to claim 6, wherein the culture medium contains chemicals ligands of mononuclear cells, for example histamine and cimetidine or a H₂ antagonist, in combination with "additional" GM-CSF, histamine being present at a concentration of about 10⁻² M to about 10⁻⁶ M, preferably of about 10⁻⁴ M, cimetidine or the H₂ antagonist being present at a concentration of about 10⁻⁴ M to about 10⁻⁹ M, preferably of about 10⁻⁶ M, and additional GM-CSF being present at a concentration of about 50 U/ml to about 2000 U/ml, preferably of about 500 U/ml.

9. Process according to any one of claims 6 to 8, comprising :

- isolation of leukocytes, from healthy donors or from patients, from peripheral blood by apheresis and removal platelets and anticoagulant from the apheresis product,
- isolation of mononuclear cells (monocytes + lymphocytes) from red cells and granulocytes in order to have less than 10% granulocytes and less than 5% red cells,
- culture of the mononuclear cells obtained at the previous stage by placing them in an appropriate culture medium containing chemical ligands of mononuclear cells, such as histamine or an agonist of histamine, an H₂ antagonist, such as cimetidine, in combination or not with GM-CSF, for a time sufficient to obtain differentiated MD-APCs, preferably for about 5 to 15 days, and possibly separating the MD-APCs from the lymphocytes, and recovering the MD-APCs or the macrophages and lymphocytes.

10. Process according to any one of claims 6 to 9, wherein the culture medium of MD-APCs is added

- with crude antigens, for instance autologous tumor membrane, killed tumoral cells, bacterial capsides, viral homogenates cleared from nucleic acids,
- specific peptides against which an immune response is desired,
- cDNA or genetic material linked to vectors (for example gluconated polylysine) to allow transfection of the MD-APCs with material coding for the relevant peptide or protein to be presented on the macrophage membrane and against which an immune response is desired,
- or bispecific antibodies targeting on the one side, a surface antigen of the MD-APCs and, on the other side, a relevant antigen against which an immune response is desired.

11. MD-APCs liable to be obtained according to the process of any one of claims 6 to 10.

12. Pharmaceutical compositions containing as active substance,
MD-APCs according to any one of claims 1 to 5 or 11.

13. Cellular vaccine compositions containing as active substance,
MD-APCs according to any one of claims 1 to 5 or 11.

14. Medium containing elements necessary for the growth and differentiation of monocytes into MD-APCs according to claims 1 to 5 or 11, and in addition containing chemical ligands of mononuclear cells, for example histamine, cimetidine in combination or not with GM-CSF.

15. Cell processor or kit containing :

- means for the recovery of lymphocytes and monocytes free of contaminants,
- appropriate buffer and wash solutions and possibly appropriate means for the conservation of MD-APCs,
- means for preparing a culture for the monocytes and possibly the lymphocytes and containing chemical ligands of mononuclear cells, for example histamine, cimetidine or a H₂ antagonist in combination or not with GM-CSF,
- possibly means for transfection of cultured cells and means for targeting antigens to MD-APCs.

16. Cell processor or kit according to claim 15, containing :

- means for recovering and centrifuging blood to obtain a leukocyte concentrate,
- means for separating lymphocytes and monocytes from the other white cells and for eliminating the contaminating red cells,
- culture medium for MD-APCs and possibly lymphocytes with complements and particularly chemical ligands of mononuclear cells, for example histamine and cimetidine or a H₂ antagonist, in combination or not with GM-CSF,
- appropriate means for the conservation of MD-APCs,
- appropriate buffer and wash solution.

17. Products containing MD-APCs according to any one of claims 1 to 5 or 11, and lymphocytes, as a combined preparation for simultaneous, separate or sequential use in cell therapy.

18. Products according to claim 17, characterized in that they contain the MD-APCs and the lymphocytes in a ratio of at least 20% to 50% of MD-APCs expressed in cell number.

5 19. Bispecific antibodies liable to recognize an antigen of a MD-APCs according to any one of claims 1 to 5 or 11 and an antigen of a tumoral cell or of a pathogen which is to be targeted to said MD-APCs.

10 20. Method for the clinical treatment, comprising the administration of an appropriate amount of MD-APCs according to any one of claims 1 to 5 or 11, and preferably in an amount of about 10^8 to about 5×10^9 MD-APCs.

15 21. Method according to claim 20 for the treatment of any disorder, comprising the administration of lymphocytes in an amount of about 4×10^9 to about 10×10^9 lymphocytes.

20 22. Use of chemical ligands of mononuclear cells, for example an agonist of histamine, in particular histamine, and a H_2 antagonist, in particular cimetidine, in combination or not with GM-CSF, for the preparation of MD-APCs having the following properties :

- they present on their surface :

* antigen CD14 and CD64 with a mean intensity of about 5 to about 200,

* antigen CD80 and CD86 with a mean intensity of about 20 to about 200,

25 * antigen CD40 and mannose receptor with a mean intensity of 50 to 500.
- they are substantially devoid of the surface antigens CD1a and CD1c, the presence and mean intensities respectively of CD14, CD64, CD80, CD86 and the absence of CD1a and CD1c being for instance determined by immunofluorescence staining and flow cytometry analysis,



30 - they present high phagocytosis property such as determined by the following test : said phagocytosis capacity being evaluated by an uptake of formalin fixed yeast, for example by culturing MD-APCs for 2 hours to select adherent cells, adding yeast in 1/10 mMD-APCs/yeast ratio and incubating at 37°C , 5% CO_2 atmosphere for 2-3 hours fixing by the May-Grünwald-Giemsa (MGG) staining, and the percentage of phagocytic MD-APCs being quantified for instance by
35 microscopic analysis,

- they have the property of stimulating the proliferation of allogenic lymphocytes such as determined by the following test :

allogenic primary mixed lymphocytes reaction (MLR) was carried out in 96-well microtiter plates by adding different numbers (2×10^3 to 2×10^5 in 100 μ l medium/well) of MD-APCs to 2×10^5 in 100 μ l medium/well of allogenic T cells purified from buffy coats and after 5 days incubation at 37°C, cell proliferation was assessed by a colorimetric method, such as the cleavage of tetrazolium salt WST-1 (slightly red) to Formozan (dark red) or such as Brdu incorporation during DNA synthesis.

5

1 / 1

FIG.1aFIG.1b

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/02703

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N5/08 A61K35/14 C07K16/46

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 26875 A (I.D.M. IMMUNO-DESIGNED MOLECULES) 24 November 1994 cited in the application see example see claims	1-22
A	--- ANTICANCER RESEARCH, vol. 14, no. 6B, November 1994, ATHENS, GREECE, pages 2673-2676, XP000608444 J. BARTHOLEYS ET AL.: "Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer." see the whole document --- -/-	1-4, 11-13, 17,18, 20,21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 September 1997

Date of mailing of the international search report

01.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/02703

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>IMMUNOLOGY, vol. 70, no. 2, June 1990, OXFORD, GB, pages 186-190, XP000608448 H. OKAMOTO ET AL.: "Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells." see abstract</p>	6-11,22
A	<p>--- WO 92 05793 A (MEDAREX, INC.) 16 April 1992 see claims</p>	10
P,A	<p>--- WO 96 22781 A (I.D.M. IMMUNO-DESIGNED MOLECULES) 1 August 1996 see the whole document</p>	1-22
P,A	<p>--- IMMUNOBIOLOGY, vol. 195, no. 4-5, October 1996, STUTTGART, GERMANY, pages 550-562, XP002039948 J. BARTOLEYNS ET AL.: "Immune therapy with macrophages: Present status and critical requirements for implementation." see the whole document -----</p>	1-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 97/02703

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 20 and 21
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int: International Application No
PCT/EP 97/02703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426875 A	24-11-94	AU 8050494 A DE 9390311 U JP 8510118 T	12-12-94 09-05-96 29-10-96
WO 9205793 A	16-04-92	AU 667460 B AU 8869491 A CA 2093022 A EP 0553244 A JP 6502410 T	28-03-96 28-04-92 06-04-92 04-08-93 17-03-94
WO 9622781 A	01-08-96	FR 2729570 A AU 4626596 A	26-07-96 14-08-96

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/08, A61K 35/14, C07K 16/46		A1	(11) International Publication Number: WO 97/44441 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/EP97/02703 (22) International Filing Date: 15 May 1997 (15.05.97) (30) Priority Data: 96401099.5 21 May 1996 (21.05.96) EP (34) Countries for which the regional or international application was filed: GB et al. (71) Applicant (for all designated States except US): I.D.M. IMMUNO-DESIGNED MOLECULES [FR/FR]; 172, rue de Charonne, F-75011 Paris (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): CHOKRI, Mohamed [MA/FR]; 9, rue de Bitché, F-67000 Strasbourg (FR). BARTHOLEYNS, Jacques [FR/FR]; 10, rue du Royaume, F-91440 Bures-sur-Yvette (FR). ROMET-LEMONNE, Jean-Loup [FR/FR]; 8, rue de Hesse, F-75003 Paris (FR). (74) Agent: GROSSET-FOURNIER, Chantal; Grosset-Fournier & Demachy S.A.R.L., 103, rue La Fayette, F-75481 Paris Cedex 10 (FR).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NEW ANTIGEN PRESENTING CELLS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS CELLULAR VACCINES			
(57) Abstract The invention relates to monocytes derived antigen presenting cells (MD-APCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200; antigen CD80 and CD86 with a mean intensity of about 20 to about 200; antigen CD40 and mannose receptor with a mean intensity of 50 to 500; they are substantially devoid of the surface antigens CD1a and CD1c; they present a phagocytosis property; they have the property of stimulating the proliferation of allogenic lymphocytes.			

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/02703

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>IMMUNOLOGY, vol. 70, no. 2, June 1990, OXFORD, GB, pages 186-190, XP000608448 H. OKAMOTO ET AL.: "Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells." see abstract</p> <p style="text-align: center;">---</p>	6-11,22
A	<p>WO 92 05793 A (MEDAREX, INC.) 16 April 1992 see claims</p> <p style="text-align: center;">---</p>	10
P,A	<p>WO 96 22781 A (I.D.M. IMMUNO-DESIGNED MOLECULES) 1 August 1996 see the whole document</p> <p style="text-align: center;">---</p>	1-22
P,A	<p>IMMUNOBIOLOGY, vol. 195, no. 4-5, October 1996, STUTTGART, GERMANY, pages 550-562, XP002039948 J. BARTOLEYNS ET AL.: "Immune therapy with macrophages: Present status and critical requirements for implementation." see the whole document</p> <p style="text-align: center;">-----</p>	1-22

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/02703

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N5/08 A61K35/14 C07K16/46

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 26875 A (I.D.M. IMMUNO-DESIGNED MOLECULES) 24 November 1994 cited in the application see example see claims	1-22
A	--- ANTICANCER RESEARCH, vol. 14, no. 6B, November 1994, ATHENS, GREECE, pages 2673-2676, XP000608444 J. BARTHOLEYNS ET AL.: "Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer." see the whole document --- -/--	1-4, 11-13, 17,18, 20,21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

5 September 1997

Date of mailing of the international search report

01.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int: onal Application No

PCT/EP 97/02703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426875 A	24-11-94	AU 8050494 A DE 9390311 U JP 8510118 T	12-12-94 09-05-96 29-10-96
WO 9205793 A	16-04-92	AU 667460 B AU 8869491 A CA 2093022 A EP 0553244 A JP 6502410 T	28-03-96 28-04-92 06-04-92 04-08-93 17-03-94
WO 9622781 A	01-08-96	FR 2729570 A AU 4626596 A	26-07-96 14-08-96

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 97/02703

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 20 and 21
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.